Anti-diabetic drug raises risk of bladder cancer

4th April 2016

The drug pioglitazone - which is said to help against diabetes - increases the risk of bladder cancer by 63 per cent, according to claims from The Daily Telegraph.

However, the actual risk in the real world is much smaller but these statistics might change the decisions of doctors with regards to the prescriptions they give their patients, reports NHS.uk.

Pioglitazone is designed to help sufferers of Type 2 diabetes, as it makes their cells more sensitive to insulin.

There have been previous studies that have linked this drug with an increased risk of bladder cancer, but overall, the results are inconclusive.

A recent study has looked at 145,806 people who took the pill over other oral diabetes drugs over 14 years, beginning from 2000.

Researchers found that those who had taken pioglitazone, instead of other diabetes drugs, were 63 per cent more likely to have been diagnosed with bladder cancer. The risk factor increased, the longer they had taken it.

Posted by Jeanette Royston

 

Health News is provided by Axonn Media in collaboration with Spire Healthcare. Please note that all copy above is ©Axonn Media and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:

or

Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.

or

Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...

Categories

Cancer

© Spire Healthcare Group plc (2016)